HealthQuill Drugs
Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Drugs Health Pharma

Bill Gates to spend $912 million to fight AIDS, tuberculosis, malaria

Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Read More
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
At least 12 people have died, and 740 new patients were admitted to hospitals as dengue cases in the South Asian nation of Bangladesh registered the largest single-day rise last week.
Climate Drugs Health

Bangladesh reports highest single-day rise in dengue cases last week

At least 12 people have died, and 740 new patients were admitted to hospitals as dengue cases in the South Asian nation of.

Read More
The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can be administered under the skin for adults.
Drugs Health Pharma

US approves Merck’s skin injectable version of cancer drug Keytruda

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health

AstraZeneca’s asthma drug fails end-stage trial in COPD

HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for.

Read More
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.
Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory.

Read More
The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.
Drugs

FDA warns Alzheimer patients on Leqembi to seek earlier scanning

HQ Team August 30, 2025: The U.S. Food and Drug Administration (FDA) is recommending an additional magnetic resonance imaging in Alzheimer’s disease patients.

Read More
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More